DHEA: The Forgotten Hormone — What It Does, Why It Declines, and Should You Replace It?

When discussing hormones and aging, testosterone, estrogen, thyroid, and growth hormone usually receive the most attention.

However, another hormone plays an important role in the body’s endocrine system: dehydroepiandrosterone, commonly known as DHEA.

Produced primarily by the adrenal glands, DHEA serves as a precursor for several sex hormones, including testosterone and estrogen.

Unlike many hormones that fluctuate throughout adulthood, DHEA follows a relatively predictable age-related pattern.

Production increases during adolescence, reaches its highest levels in early adulthood, and then progressively declines with age.

By the seventh or eighth decade of life, circulating DHEA sulfate (DHEA-S) concentrations may be substantially lower than those observed in young adults.

This decline has generated considerable interest in whether replacing DHEA might improve energy, sexual function, muscle mass, metabolic health, or even slow aspects of biological aging.

But an important question remains:

Does declining DHEA contribute to aging, or is it simply another biological marker of the aging process?

Understanding the distinction is essential before considering supplementation.

DHEA is a steroid hormone synthesized primarily in the zona reticularis of the adrenal cortex.

Smaller amounts are produced by the ovaries and testes, and DHEA can also be synthesized within certain peripheral tissues.

Its production begins with cholesterol, the fundamental building block for steroid hormones.

However, steroid hormone metabolism is considerably more complex than this simplified sequence suggests.

DHEA can be converted into androstenedione, testosterone, and estrogens through multiple enzymatic pathways.

These conversions occur in different tissues and are influenced by enzyme activity, age, sex, and underlying hormonal conditions.

Importantly, not all DHEA is converted into testosterone or estrogen.

Much of it circulates as DHEA-S, a sulfated form that serves as a large circulating reservoir of adrenal androgen precursors.

DHEA and DHEA-S can also participate in biological processes independent of their conversion into sex hormones.

This includes potential interactions with neurological signaling, although the clinical significance of these effects remains incompletely understood.

Although closely related, DHEA and DHEA-S are not identical.

DHEA is the unconjugated hormone that can undergo conversion into other steroid hormones.

DHEA-S is the sulfated form, produced through the action of sulfotransferase enzymes.

DHEA-S circulates at much higher concentrations and has a longer biological half-life than DHEA.

It also exhibits considerably less variation throughout the day.

For these reasons, DHEA-S is generally the preferred laboratory measurement when evaluating adrenal androgen production.

However, measuring DHEA-S does not directly reveal how much testosterone or estrogen an individual’s tissues are producing from DHEA.

That distinction becomes particularly important when interpreting laboratory results or considering supplementation.

DHEA production begins increasing during childhood through a process known as adrenarche.

Levels continue rising through adolescence and generally peak during the second or third decade of life.

After early adulthood, circulating DHEA-S concentrations gradually decline.

This process is sometimes referred to as adrenopause.

Unlike menopause, however, adrenopause does not represent a sudden loss of endocrine function.

Instead, it reflects a gradual reduction in adrenal androgen production over several decades.

The decline appears to involve age-related changes in the adrenal zona reticularis and its steroid-producing capacity.

Importantly, this process is not simply caused by reduced ACTH stimulation.

ACTH continues to regulate adrenal steroidogenesis, but the aging adrenal gland changes how it responds and which hormones it produces.

Consequently, cortisol production may remain relatively preserved while DHEA production decreases substantially.

Not necessarily.

DHEA-S is frequently described as a biomarker of aging because its circulating concentration declines with age.

However, a biomarker is not automatically a cause of the process it reflects.

Gray hair, for example, becomes more common with age, but restoring hair color does not reverse biological aging.

Similarly, restoring DHEA concentrations to youthful levels does not necessarily restore youthful physiology.

Some observational studies have associated lower DHEA-S concentrations with frailty, poorer physical function, or adverse health outcomes.

However, observational associations cannot establish causation.

Lower DHEA-S may reflect underlying illness, physiological stress, altered adrenal function, or other age-related changes rather than directly causing these conditions.

This distinction is central to evaluating DHEA as a potential longevity intervention.

One of DHEA’s most established biological functions is serving as a precursor for androgen and estrogen synthesis.

This function is particularly important in women.

After menopause, ovarian estrogen production decreases substantially.

Peripheral tissues continue producing small amounts of estrogens and androgens through the conversion of circulating steroid precursors, including DHEA.

This process is known as intracrinology.

Intracrinology describes the production and action of hormones within individual tissues, sometimes without substantial release of those active hormones into the circulation.

For example, DHEA may be converted into active sex steroids within skin, adipose tissue, or reproductive tissues.

The resulting hormonal activity may therefore differ between tissues even when circulating DHEA-S concentrations are similar.

This helps explain why DHEA supplementation does not produce identical hormonal responses in everyone.

Because DHEA can be converted into testosterone and estrogen, researchers have investigated whether supplementation improves libido and sexual function.

The results have been inconsistent.

Some smaller studies have reported improvements in sexual well-being, particularly among women with adrenal insufficiency.

However, larger evidence reviews and professional society recommendations do not support routine systemic DHEA supplementation for sexual dysfunction in otherwise healthy women.

The 2025 International Menopause Society recommendations conclude that available evidence does not support systemic DHEA for female sexual symptoms.

An important exception involves vaginal DHEA, which has demonstrated benefits for certain symptoms associated with menopause.

We will discuss this distinction below.

DHEA and DHEA-S have been investigated for potential effects on neurological function.

Experimental research suggests that these compounds may influence several neurotransmitter systems.

These include pathways involving GABA and glutamate signaling.

Because these systems participate in mood regulation, learning, and memory, researchers have explored DHEA supplementation for depression and cognitive decline.

Some clinical studies have reported improvements in depressive symptoms.

However, the evidence remains limited by small study populations, differences in dosing, and inconsistent results.

At present, DHEA is not an established treatment for depression, cognitive impairment, or dementia.

Its potential neurological effects remain an active area of research rather than a validated anti-aging treatment.

DHEA has also attracted attention as a potential intervention for age-related muscle loss.

The biological rationale is understandable.

DHEA can contribute to androgen production, and androgens influence muscle protein synthesis and body composition.

However, increasing a hormone precursor does not necessarily produce the same physiological effects as administering an active androgen.

Clinical studies investigating DHEA supplementation in older adults have generally failed to demonstrate consistent, clinically meaningful improvements in muscle mass or strength.

Some studies have reported modest changes in body composition, but these findings have not translated into convincing evidence that DHEA prevents sarcopenia.

For preserving skeletal muscle during aging, resistance training, adequate protein intake, and correction of established hormonal deficiencies remain better-supported strategies.

Researchers have investigated whether DHEA influences abdominal fat, insulin sensitivity, and metabolic health.

Some small clinical trials have reported reductions in visceral adiposity or improvements in insulin-related measurements.

However, these findings have not been consistently reproduced across larger studies.

There is currently insufficient evidence to recommend DHEA as a treatment for obesity, insulin resistance, or metabolic syndrome.

Importantly, the relationship between DHEA-S and metabolic health may differ according to sex, age, and underlying medical conditions.

Higher DHEA-S is not universally associated with better metabolic health.

For example, elevated adrenal androgen activity can contribute to hyperandrogenic conditions in certain women.

This reinforces why hormone concentrations must be interpreted within the appropriate clinical context.

Yes.

Unlike some of the more speculative benefits attributed to DHEA, its ability to influence circulating sex hormone concentrations is supported by clinical evidence.

A 2025 meta-analysis examined 21 studies investigating DHEA supplementation in postmenopausal women.

Researchers found that supplementation increased both testosterone and estradiol concentrations.

However, these findings require careful interpretation.

The reported changes represent average differences across studies rather than predictable responses in individual patients.

Furthermore, an increase of 24 ng/dL in testosterone may be relatively modest in a man but potentially substantial in a postmenopausal woman.

The clinical consequences depend on baseline hormone concentrations, tissue sensitivity, dose, and individual metabolism.

Most importantly, increasing testosterone or estrogen concentrations does not automatically establish that DHEA supplementation improves symptoms or long-term health outcomes.

This distinction is frequently overlooked in discussions of hormone optimization.

One of the more clinically established situations in which DHEA replacement may be considered is primary adrenal insufficiency.

In this condition, the adrenal glands cannot produce adequate amounts of certain hormones.

Patients typically require replacement of glucocorticoids and, when indicated, mineralocorticoids.

However, conventional adrenal replacement therapy does not restore adrenal androgen production.

Women with primary adrenal insufficiency may therefore experience very low DHEA concentrations.

Some report persistent fatigue, reduced libido, or depressive symptoms despite otherwise adequate adrenal hormone replacement.

Importantly, this is a conditional recommendation based on limited evidence.

It does not mean that every patient with adrenal insufficiency requires DHEA.

It also does not justify routine DHEA supplementation in otherwise healthy individuals.

DHEA is frequently marketed as an anti-aging supplement.

From these observations, it is tempting to conclude that restoring DHEA might reverse some of these changes.

However, this reasoning contains an important scientific limitation.

A hormone declining with age does not prove that replacing it will reverse the biological consequences of aging.

Aging involves numerous interconnected processes, including mitochondrial dysfunction, cellular senescence, altered nutrient sensing, chronic inflammation, genomic instability, and changes in cellular communication.

DHEA participates in endocrine signaling, but there is no convincing evidence that supplementation reverses these fundamental aging mechanisms in humans.

Nor have randomized clinical trials demonstrated that DHEA supplementation extends human lifespan.

At present, DHEA should not be considered a proven longevity intervention.

DHEA-S testing can be useful in selected clinical circumstances.

For example, DHEA-S may be measured when evaluating suspected adrenal androgen excess, certain cases of hirsutism, or specific adrenal disorders.

It can also help monitor DHEA replacement in selected patients with adrenal insufficiency.

However, routine DHEA-S screening is not recommended for every adult simply because they are aging.

A low DHEA-S concentration in an older individual may reflect normal age-related physiology.

Laboratory reference intervals vary substantially with age and sex.

Therefore, comparing a 65-year-old patient’s DHEA-S concentration with that of a healthy 25-year-old can be misleading.

Similarly, a single low result does not establish a diagnosis of adrenal insufficiency.

When adrenal insufficiency is suspected, appropriate testing generally involves cortisol and ACTH evaluation rather than relying on DHEA-S alone.

The goal of laboratory testing should be to answer a specific clinical question, not simply identify every hormone that has declined with age.

Not automatically.

This is perhaps the most important practical consideration.

A laboratory result below a youthful reference range does not necessarily indicate a pathological hormone deficiency.

For example, fatigue may result from poor sleep, obstructive sleep apnea, anemia, thyroid dysfunction, depression, medication effects, or numerous other conditions.

Finding a relatively low DHEA-S concentration does not establish that DHEA is responsible.

Similarly, reduced sexual desire may involve hormonal, psychological, relational, medication-related, or medical factors.

Treating a laboratory value without understanding the underlying problem may expose patients to unnecessary risks without addressing the actual cause of their symptoms.

DHEA and testosterone are distinct hormones with different physiological roles.

Testosterone replacement therapy directly increases testosterone exposure.

DHEA supplementation provides additional steroid precursors that may undergo conversion into testosterone, estrogen, and other metabolites.

For men receiving testosterone replacement therapy, adding DHEA has not been shown to consistently improve treatment outcomes.

Furthermore, testosterone replacement does not inherently create a need for DHEA supplementation.

In women receiving testosterone therapy, adding DHEA may increase androgen exposure and potentially contribute to unwanted effects.

Therefore, DHEA should not automatically be included in a hormone replacement regimen.

Any decision to combine therapies should be based on a clear clinical rationale, relevant laboratory findings, and careful monitoring.

DHEA is an important component of human steroid hormone physiology.

It serves as a precursor for testosterone and estrogen, participates in tissue-specific hormone production, and declines substantially with age.

However, its biological importance should not be confused with proof that supplementation improves health.

Research demonstrates that DHEA can increase circulating sex hormone concentrations, particularly in postmenopausal women.

Yet evidence supporting improvements in muscle mass, metabolic health, sexual function, cognitive performance, or longevity remains inconsistent or insufficient.

There are specific clinical situations in which DHEA treatment may be appropriate, including selected women with primary adrenal insufficiency and postmenopausal women receiving FDA-approved vaginal prasterone for painful intercourse.

Outside these circumstances, routine supplementation is not supported by strong clinical evidence.

At R2 Medical Clinic, our approach to hormone health emphasizes individualized evaluation, appropriate laboratory testing, and treatment decisions based on both clinical evidence and patient-specific needs.

The objective of hormone optimization should not be to recreate the laboratory values of a 25-year-old. It should be to identify clinically meaningful abnormalities and improve health outcomes using treatments supported by evidence.

DHEA is an important hormone.

Whether replacing it improves health is an entirely different question.

Hormonal changes are a normal part of aging, but symptoms such as fatigue, changes in sexual function, and reduced physical performance deserve a thoughtful medical evaluation.

At R2 Medical Clinic, we focus on understanding the underlying causes of hormonal symptoms rather than treating laboratory numbers in isolation.

Our individualized approach combines clinical assessment, laboratory testing, and evidence-based treatment options when medically appropriate.

Schedule a consultation with R2 Medical Clinic to learn more about your hormonal health and available treatment options.